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Abstract
Background: The aim of this study was to assess significance of serum neutrophil gelatinase-associated lipocalin
(sNGAL) and cystatin C (sCC) in prediction of adverse cardiovascular outcome after ST-segment elevation
myocardial infarction (STEMI).
Methods: We recruited 357 consecutive patients who were admitted to the hospital within 24 h after onset of
STEMI. On the 1st and 12th-14th day after hospital admission, we measured levels of sNGAL and sCC. We also
determined presence of renal dysfunction (RD), defined as glomerular filtration rate < 60 mL/min/1.73 m2. After
3 years of follow-up, we performed a logistic regression and assessed the value of RD, sNGAL, and sCC in prediction
of combined endpoint, defined as cardiovascular death or any cardiovascular complication.
Results: RD, sCC level ≥ 1.9 mg/L, and sNGAL level ≥ 1.25 ng/mL on the 12th-14th day of hospitalization were
associated with a 1.6-fold, 1.9-fold, and 2.9-fold higher risk of adverse cardiovascular outcome, respectively. Area
under the ROC curve was the highest for the model based on sNGAL level compared to the models based on sCC
level or RD presence.
Conclusions: Measurement of sNGAL level in patients with STEMI on the 12th-14th day after hospital admission
may improve prediction of adverse cardiovascular outcome.
Keywords: ST-segment elevation myocardial infarction, Renal dysfunction, Glomerular filtration rate, Cystatin C,
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Background
According to the World Health Organization statistics,
coronary artery disease (CAD) is a leading cause of
death worldwide [1]. An estimated 7.4 million people
died from CAD in 2012, representing 11.2% of all global
deaths [1]. In the Russian Federation alone, there were
597,921 deaths from CAD, which is the highest number
amongst all countries included into analysis [1].
A number of investigations revealed a significant asso-
ciation of renal dysfunction [RD, defined as glomerular
filtration rate (GFR) < 60 mL/min/1.73 m2] with a high
risk of cardiovascular death or acute cardiovascular
events [2–4]. Moreover, RD is significantly associated
with an adverse cardiovascular outcome in patients with
CAD [5]. A critical decrease in GFR and albuminuria
commonly occur at the late stage of chronic kidney dis-
ease (CKD) when > 30% of nephrons are affected [6].
However, there is a crucial need in novel, highly sensitive
and specific markers of RD at the early stages of CKD.
Recently, serum cystatin C (sCC) and serum neutrophil
gelatinase-associated lipocalin (sNGAL) were suggested
as the promising candidates [7, 8].
It is known that CC arises in all nucleated cells and is
one of the most important endogenous inhibitors of
cysteine proteinases whilst NGAL is produced by tubular
epithelial cells and neutrophils in response to inflamma-
tion or ischemia, inhibiting bacterial growth and indu-
cing epithelial cell proliferation [9]. The diagnostic value
of sCC and sNGAL was shown for acute kidney in-
jury, progression of CKD, and acute cardiorenal syn-
drome [10, 11]. Moreover, there is growing evidence
of sCC and sNGAL importance in atherosclerosis and
myocardial remodeling [12, 13]. In addition, sCC and
sNGAL are associated with the risk factors of athero-
sclerosis [14, 15].
We carried out this study with the aim to investigate
the value of sCC and sNGAL in prediction of an adverse
cardiovascular outcome after ST-segment elevation myo-
cardial infarction (STEMI).
Methods
We recruited 357 patients who were admitted within
24 h of STEMI onset to Research Institute for Complex
Issues of Cardiovascular Diseases (Kemerovo, Russian
Federation) in 2012–2013. The study was performed in
accordance with the principles of Good Clinical Practice
and the Declaration of Helsinki. The local ethical com-
mittee approved the study and all the participants
provided written informed consent after a full explan-
ation of the study was given to them.
The criteria of inclusion into the study were 1) age >
18 years; 2) diagnosis of STEMI according to the European
Society of Cardiology (ESC) Guidelines [16]; 3) written
informed consent to participate in the study. Criteria of
exclusion were 1) age < 18 years; 2) past medical history of
cancer, concomitant autoimmune and/or mental disorders;
3) recurrent MI after percutaneous coronary intervention
(PCI) or coronary artery bypass graft (CABG) surgery.
Stable angina, congestive heart failure, arterial hyperten-
sion, hypercholesterolemia, and diabetes mellitus were di-
agnosed according to ESC guidelines on the management
of stable CAD [17], ESC guidelines for the diagnosis and
treatment of acute and chronic heart failure [18], ESH/
ESC Guidelines for the management of arterial hyperten-
sion [19], ESC/EAS Guidelines for the management of
dyslipidemias [20], and ESC/EASD Guidelines on dia-
betes, pre-diabetes, and cardiovascular diseases [21], re-
spectively. Smoking, body mass index, past medical
history of MI or stroke, and family history of CAD were
defined using the medical records. Clinicopathological fea-
tures of the patients are represented in Table 1.
Selective coronary angiography was performed within
the first hours after hospital admission using GE Health-
care Innova 3100 Cardiac Angiography System (General
Electric Healthcare). Colour duplex screening of the ex-
tracranial arteries (ECA) and lower extremity arteries
(LEA) was performed on the 5th-7th day after hospital
admission in all patients using the cardiovascular ultra-
sound system Vivid 7 Dimension (General Electric
Healthcare) with a 5.7 MHz linear array transducer (for
ECA), a 2.5–3 MHz curved array transducer, and a
Table 1 Clinicopathological features of the patients, n = 357
Feature Value
Female gender, n (%) 99 (27.7)
Mean age, years (95% confidence interval) 61.3 (59.9–62.6)
Stable angina, n (%) 176 (49.3)
Congestive heart failure, n (%) 75 (21.0)
Arterial hypertension, n (%) 301 (84.3)
Hypercholesterolemia, n (%) 87 (24.4)
Diabetes mellitus, n (%) 60 (16.8)
Smoking, n (%) 180 (50.4)
Body mass index > 25 kg/m2, n (%) 265 (74.2)
Past medical history of myocardial infarction, n (%) 65 (18.2)
Past medical history of stroke, n (%) 31 (8.7)
Family history of coronary artery disease, n (%) 91 (25.5)
Table 2 In-hospital non-lethal cardiovascular complications,
n = 357
Complication Value
Early postinfarction angina, n (%) 50 (14.0)
Recurrent myocardial infarction, n (%) 18 (5.0)
Stroke, n (%) 2 (0.6)
Arrhythmia or heart block, n (%) 96 (26.9)
Any non-lethal cardiovascular complications, n (%) 166 (46.5)
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5 MHz linear array transducer (for LEA). An extent of
arterial stenosis was assessed in B regimen and by dop-
plerography (visualizing the local haemodynamics in the
stenosis zone). Common and internal carotid arteries,
vertebral, and subclavian arteries were visualized from
both sides during the ECA screening; common and deep
femoral arteries, popliteal, anterior and posterior tibial ar-
teries were visualized from both sides during the LEA
screening. The intima-media thickness (IMT) of common
carotid artery was measured in the automatic mode (the
value < 1 mm was considered normal). Polyvascular dis-
ease was defined as an increase in IMT ≥ 1 mm or ECA
and/or LEA stenosis.
The preferable methods of myocardial reperfusion
were defined in the shortest terms and included PCI or
systemic thrombolytic therapy (TLT). Myocardial revas-
cularization was not conducted when technical problems
occurred or in patients with complex coronary anatomy
or those with contraindications to TLT or PCI. All pa-
tients received the standard therapy of unfractionated
heparin, aspirin, clopidogrel, angiotensin-converting en-
zyme inhibitors, beta-blockers, and statins. Long-acting
nitrates, calcium channel blockers, diuretics, inotropic
and antiarrhythmic drugs were prescribed if needed.
Serum creatinine level was measured at hospital ad-
mission and before hospital discharge with the further
calculation of GFR by Modification of Diet in Renal Dis-
ease (MDRD) formula. In the case of in-hospital death,
the final level of serum creatinine was taken into
account. RD was defined as GFR < 60 mL/min/1.73 m2.
The levels of sCC and sNGAL were measured on the 1st
and 12th-14th day after hospital admission by enzyme-
linked immunosorbent assay using the respective kits of
R&D Systems according to the manufacturer’s protocols.
Reference values for sCC were 0.52–0.90 mg/L and
0.56–0.98 mg/L for females and males, respectively.
Reference values for sNGAL were 0.037–0.106 ng/mL.
In-hospital case fatality rate was 10.4% (37/357 pa-
tients). The prevalence of in-hospital non-lethal cardio-
vascular complications is represented in Table 2. After
3 years of follow-up, we collected data from 87.8% (281/
320) discharged patients. Follow-up was conducted by a
telephone-based interview. Cardiovascular death, recur-
rent MI, stroke, hospital admission due to unstable
angina, and acute decompensated heart failure were
considered as an adverse cardiovascular outcome, or the
study endpoints. The prevalence of the study endpoints
is represented in Table 3.
Statistical analysis was performed using MedCalc
(MedCalc Software) and SPSS (IBM). A sampling distri-
bution was assessed by D’Agostino-Pearson test. De-
scriptive data were represented by median, interquartile
range (25th and 75th percentiles), mean, and standard
deviation of the mean. Two independent groups were
compared by Mann-Whitney U-test. An adjustment for
multiple comparisons was performed using false discov-
ery rate (FDR). P-values, or q-values if FDR was applied
(q-values are the name given to the adjusted p-values
found using an optimized FDR approach), ≤ 0.05 were
regarded as statistically significant. For multivariate ana-
lysis, we performed a stepwise linear logistic regression
using forward Wald method with the plotting of the re-
ceiver operating characteristic (ROC) curve and further
calculation of the area under the curve (AUC). Cut-off
levels for sCC and sNGAL were defined according to
the linear logistic regression to determine the optimal
predictive values but were not linked to GFR.
Results
At hospital admission, all the patients were divided into
two groups, with (n = 104, 29.1%) and without (n = 253,
70.9%) RD. The same stratification was carried out be-
fore hospital discharge [n = 86 (24.1%) and n = 271
(75.9%) patients with and without RD, respectively].
Medians of sCC and sNGAL levels on the 1st day after
hospital admission were 1.21 (0.89–1.63) mg/L and 1.33
Table 3 Study endpoints after 3 years of follow-up, n = 281
Study endpoint Value
Cardiovascular death, n (%) 43 (15.3)
Recurrent myocardial infarction, n (%) 40 (14.2)
Stroke, n (%) 12 (4.3)
Hospital admission due to unstable angina, n (%) 81 (28.8)
Acute decompensated heart failure, n (%) 23 (8.2)
Combined endpoint, n (%) 199 (70.8)
Table 4 Concentrations of serum cystatin C and neutrophil gelatinase-associated lipocalin in patients with and without renal
dysfunction at hospital admission, n = 357
Feature Renal dysfunction at
hospital admission, n = 104
No renal dysfunction at
hospital admission, n = 253
P value
Serum cystatin C on the 1st day after hospital admission, mg/L 1.76 (1.06–1.96) 1.16 (0.86–1.34) 0.037
Serum cystatin C on the 12th-14th day after hospital admission, mg/L 1.75 (1.15–2.16) 1.31 (0.95–1.66) 0.001
Serum neutrophil gelatinase-associated lipocalin on the 1st day after
hospital admission, ng/mL
1.41 (1.01–1.82) 1.36 (1.08–1.64) 0.95
Serum neutrophil gelatinase-associated lipocalin on the 12th-14th day
after hospital admission, ng/mL
1.78 (1.43–2.12) 1.85 (1.65–2.06) 0.68
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(0.36–1.91) ng/mL, respectively. Medians of sCC and
sNGAL levels on the 12th-14th day after hospital admis-
sion were 1.50 (1.02–1.90) mg/L and 1.63 (1.25–2.62)
ng/mL, respectively.
Patients with RD at hospital admission had significantly
higher levels of sCC on the 1st and 12th-14th day after
hospital admission [1.76 (1.06–1.96) and 1.75 (1.15–2.16)
mg/L, respectively) compared to those without RD [1.16
(0.86–1.34) and 1.31 (0.95–1.66) mg/L], p = 0.037 and
0.001, respectively (Table 4). Patients with RD at hospital
discharge had significantly higher levels of sCC [1.74
(1.29–2.17) mg/L] and sNGAL [1.93 (1.55–2.52) ng/mL]
on the 12th-14th day after hospital admission in compari-
son with those without RD [1.41 (0.96–1.7) mg/L and 1.53
(1.18–2.62) ng/mL], p = 0.024 and 0.031, respectively
(Table 5). Regarding all other comparisons, we did not
find any significant differences.
An increased level of sNGAL on the 1st day after admis-
sion was significantly associated with in-hospital non-
lethal cardiovascular complications [1.42 (1.17–2.27) and
1.20 (0.20–1.86) ng/mL in patients with and without
them, respectively, p = 0.019]. Moreover, a higher level of
sNGAL on the 12th-14th day after hospital admission was
significantly associated with a cardiovascular death after
3 years of follow-up (Fig. 1). In addition, elevated concen-
trations of sCC and sNGAL on the 12th-14th day after
hospital admission were significantly associated with a
combined endpoint (Figs. 1 and 2). Notably, 132 patients
had a level of sNGAL ≥ 1.25 ng/mL at hospital discharge
that could possibly point on an infection [9]; however,
none of them had signs or symptoms of any infectious dis-
ease both at hospital admission and hospital discharge.
Nevertheless, we did not perform a specialized screening
for latent infections.
For the determination of the independent factors of an
adverse cardiovascular outcome, we performed a step-
wise linear logistic regression. Factors included into re-
gression were age, gender, past medical history of MI or
stroke, diabetes mellitus, arterial hypertension, smoking,
Killip class of acute heart failure at hospital admission,
left ventricular ejection fraction (LVEF), localization of
MI, number of affected coronary arteries, polyvascular
disease, myocardial revascularization, sCC or sNGAL
level on the 12th-14th day after hospital admission, and
RD before hospital discharge. We identified anterior MI,
LVEF < 40%, 3 affected coronary arteries, past medical
history of stroke, level of sCC ≥ 1.9 mg/L on the 12th-
14th day after hospital admission, level of sNGAL ≥
1.25 ng/mL on the 12th-14th day after hospital admis-
sion, and RD before hospital discharge as the factors
significantly associated with an adverse cardiovascular
outcome after 3 years of follow-up (Table 6). Perform-
ance of PCI was associated with a significant decrease in
risk of an adverse cardiovascular outcome (Table 6).
Finally, we compared AUC of the models based on RD
before hospital discharge, level of sCC ≥ 1.9 mg/L, and
level of sNGAL ≥ 1.25 ng/mL on the 12th-14th day after
Table 5 Concentrations of serum cystatin C and neutrophil gelatinase-associated lipocalin in patients with and without renal
dysfunction before hospital discharge, n = 357
Feature Renal dysfunction before
hospital discharge, n = 86
No renal dysfunction before
hospital discharge, n = 271
P value
Serum cystatin C on the 1st day after hospital admission, mg/L 1.27 (1.04–1.69) 1.12 (0.95–1.4) 0.14
Serum cystatin C on the 12th-14th day after hospital admission, mg/L 1.74 (1.29–2.17) 1.41 (0.96–1.7) 0.024
Serum neutrophil gelatinase-associated lipocalin on the 1st day after
hospital admission, ng/mL
1.42 (1.05–2.28) 1.23 (0.2–1.76) 0.06
Serum neutrophil gelatinase-associated lipocalin on the 12th-14th day
after hospital admission, ng/mL
1.93 (1.55–2.52) 1.53 (1.18–2.62) 0.031
Fig. 1 Medians of sNGAL levels on the 12th-14th day after hospital
admission depending on cardiovascular outcome after 3 years
of follow-up
Fig. 2 Medians of sCC levels on the 12th-14th day after hospital admission
depending on cardiovascular outcome after 3 years of follow-up; the Y axis
is cut from 0 to 1.46 for the better visualization of the results
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hospital admission. The latter model had the highest
predictive value (AUC = 0.78) whilst two other models
had equally lower predictive value (AUC = 0.70, Fig. 3).
Discussion
In this study, we assessed the value of sCC and sNGAL
level in prediction of an adverse cardiovascular outcome
after STEMI. While sCC is a well-established marker of
GFR [22, 23], sNGAL is mainly a neutrophil biomarker
related to the bacterial infections; however, a number of
studies also demonstrated an increase in sNGAL as a re-
sponse to renal tubular damage [24–26]. Despite sNGAL
is not well-recognized GFR marker compared to sCr and
sCC and is not used for the calculation of GFR, sCr,
sCC, and sNGAL all being the markers of renal tubular
damage can be compared directly to each other for esti-
mating efficiency in prediction of adverse outcome.
We previously demonstrated that sCC measured 1 day
before and 7 days after CABG surgery is an appropriate
predictor of in-hospital adverse cardiovascular and renal
outcomes [27]. Here we showed that sCC and sNGAL
can be potential markers of RD in patients with STEMI
if measured on the 12th-14th day after hospital admis-
sion. Moreover, the level of sCC ≥ 1.9 mg/L and level of
sNGAL ≥ 1.25 ng/mL on the 12th-14th day after hospital
admission were associated with an adverse cardiovascu-
lar outcome in these patients after 3 years of follow-up.
Out of three predictive models based on GFR < 60 mL/
min/1.73 m2, level of sCC ≥ 1.9 mg/L, and level of
sNGAL ≥ 1.25 ng/mL on the 12th-14th day after hospital
admission, the latter had the highest predictive value.
This corresponds to the results of Akerblom et al. who
identified high level of sCC as an independent predictor
of cardiovascular death or MI in patients with acute cor-
onary syndrome (ACS) after 1 year of follow-up [28]. In
Table 6 Independent predictors of an adverse cardiovascular outcome after 3 years of follow-up
Predictor P value Odds ratio 95% confidence interval
Lower bound Upper bound
Anterior localization of myocardial infarction 0.009 2.3 1.2 4.1
Left ventricular ejection fraction < 40% 0.001 3.6 1.7 7.6
Three affected coronary arteries 0.022 2.0 1.1 3.7
Past medical history of stroke 0.001 1.6 1.2 2.2
Level of serum cystatin C on the 12th-14th day after hospital
admission≥ 1.9 mg/L
0.004 1.9 1.2 2.9
Level of serum neutrophil gelatinase-associated lipocalin on
the 12th-14th day after hospital admission≥ 1.25 ng/mL
0.003 2.9 1.4 6.0
Renal dysfunction before hospital discharge 0.001 1.6 1.2 2.2
Percutaneous coronary intervention 0.001 0.4 0.3 0.7
Fig. 3 Comparison of the predictive value of the models based on different markers of renal dysfunction regarding adverse cardiovascular outcome
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addition, our results are in accordance with the data of
Lindberg et al. who detected that high level of sNGAL is
an independent predictor of an adverse cardiovascular
outcome after 2 years of follow-up in patients with
STEMI who underwent PCI [29]. Noteworthy, one of
the recent studies demonstrated that a multimarker
approach using sCC and a number of other bio-
markers added prognostic information to the GRACE
risk score in patients with ACS and high risk defined
by GRACE, with increasing 6-month mortality in pa-
tients with a higher number of elevated biomarkers at
hospital admission [30].
In our study, 39 patients were lost to follow-up; how-
ever, all of them were alive at that moment. Out of them,
17 (43.6%) patients had major cardiovascular risk factors,
i.e., diabetes mellitus, CKD, or arterial hypertension; 15
(38.5%) and 24 (61.5%) respectively had cardiovascular
complications and a decrease in GFR during the hospital
stay. All these variables were comparable to the general
sample; hence, exclusion of the patients lost to follow-up
from the statistical analysis was unlikely to affect the re-
sults. However, this still can be considered as a study limi-
tation along with a single-center design.
Therefore, both sCC and sNGAL have high predictive
value for the stratification of cardiovascular risk in pa-
tients with STEMI; however, sNGAL has an advantage
over sCC.
Conclusion
Patients with STEMI and in-hospital RD have higher
levels of sCC and sNGAL compared to those without in-
hospital RD. Elevated concentrations of sCC and sNGAL
on the 12th-14th day after hospital admission can be
suggested as the significant predictors of an adverse car-
diovascular outcome in these patients after 3 years of
follow-up. The model based on increased level of sNGAL
has higher predictive value compared to those based on
elevated concentration of sCC and decreased GFR.
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